Lyra Therapeutics, Inc.

Equities

LYRA

US55234L1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.72 ^USD	-8.70%		-9.06%	-9.92%

Mar. 22	Lyra Therapeutics Files $300 Million Mixed Shelf Offering	MT
Mar. 21	Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 21, 2024 at 04:12 pm EDT

Lyra Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 62.68 million compared to USD 55.28 million a year ago. Basic loss per share from continuing operations was USD 1.26 compared to USD 1.83 a year ago.

Latest news about Lyra Therapeutics, Inc.

Lyra Therapeutics Files $300 Million Mixed Shelf Offering	Mar. 22	MT
Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Lyra Therapeutics, Inc Announces Appointment of Ronan O?Brien as Chief Legal Officer	23-10-16	CI
BTIG Assumes Lyra Therapeutics at Buy With $15 Price Target	23-10-06	MT
BofA Securities Increases Price Target on Lyra Therapeutics to $15 From $13, Maintains Buy Rating	23-09-12	MT
Lyra Therapeutics Says Phase 2 Trial for Chronic Rhinosinusitis Treatment Meets Primary Endpoint	23-09-12	MT
Transcript : Lyra Therapeutics, Inc. - Special Call	23-09-12
Lyra Therapeutics Announces Positive Topline Results from Beacon Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis in Patients with Prior Ethmoid Sinus Surgery	23-09-12	CI
HC Wainwright Starts Lyra Therapeutics at Buy With $12 Price Target	23-08-31	MT
North American Morning Briefing : China Angst -2-	23-08-15	DJ
Lyra Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell Microcap Value Index	23-06-23	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 3000E Value Index	23-06-23	CI
North American Morning Briefing : Stock Futures Point to Steady Open; Saudi Cuts Boost Oil	23-06-05	DJ
Lyra Therapeutics Jumps Premarket Following Insider Share Purchases	23-06-05	MT
Insider Buy: Lyra Therapeutics	23-06-02	MT
Insider Buy: Lyra Therapeutics	23-06-02	MT
Lyra Therapeutics Closes $50 Million Private Placement	23-06-01	MT
Lyra Therapeutics, Inc. announced that it has received $44.11725 million in funding	23-05-30	CI
Lyra Therapeutics Launches $50 Million Private Placement; Shares Surge Pre-Bell	23-05-26	MT
Lyra Therapeutics, Inc. announced that it expects to receive $44.11725 million in funding	23-05-25	CI
Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Transcript : Lyra Therapeutics, Inc. Presents at Bank of America Securities 2023 Healthcare Conference, May-10-2023 04:35 PM	23-05-10
Lyra Therapeutics, Inc. Announces Commencement of Enrollment in ENLIGHTEN II	23-04-25	CI

Chart Lyra Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lyra Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.72 USD

Average target price

12 USD

Spread / Average Target

+154.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LYRA THERAPEUTICS, INC.	-9.92%	282M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research